反流性食管炎应用雷贝拉唑与莫沙必利联合治疗的临床效果及不良反应

Clinical Effects and Adverse Reactions of Combined Treatment of Rabeprazole and Mosapride on Reflux Esophagitis

目的:探讨对反流性食管炎患者予以雷贝拉唑联合莫沙必利治疗的临床效果及不良反应。方法:纳入郧西县人民医院2019年3月-2020年3月收治的89例反流性食管炎患者作为研究对象,并采用随机数字表法将其分为两组,对照组(n=44)与观察组(n=45),对照组行奥美拉唑与莫沙必利联合治疗,观察组行雷贝拉唑与莫沙必利联合治疗,观察两组治疗前、后临床症状变化情况,并对其症状轻重程度加以评估;对比两组治疗前、后血清胃泌素水平、食管下括约肌(LES)压力及pH值(LES以上5 cm);统计治疗后3个月临床疗效及用药不良反应发生情况。结果:治疗前,两组各项症状评分比较,差异无统计学意义(P>0.05),治疗后,两组各项症状评分均呈下降的趋势,但观察组各项症状评分明显更低(P<0.05);治疗前,两组血清胃泌素水平、LES压力及pH值比较,差异无统计学意义(P>0.05),治疗后,两组血清胃泌素水平、LES压力及pH值均呈明显改善的趋势,但观察组明显更优(P<0.05);观察组临床总有效率明显高于对照组(P<0.05);观察组用药不良反应发生率明显低于对照组(P<0.05)。结论:对反流性食管炎患者予以雷贝拉唑联合莫沙必利治疗的临床效果明显,不仅可以避免胃酸过度损伤食管,促进胃食管排空,防止反流发生,改善各项症状,同时还可降低用药不良反应发生率,安全性、有效性较高,值得临床大力推广并应用。

Objective:To investigate the clinical effects and adverse reactions of Rabeprazole combined with Mosapride in patients with reflux esophagitis.Method:A total of 89 patients with reflux esophagitis admitted to Yunxi County People’s Hospital from March 2019 to March 2020 were included as the research objects,and they were divided into the control group(n=44)and the observation group(n=45)by random number table method,the control group was treated with Omeprazole and Mosapride combined treatment,and the observation group was treated with Rabeprazole and Mosapride combined treatment.The clinical symptoms of the two groups were observed before and after treatment.The severity of symptoms was evaluated;the levels of serum gastrin,lower esophageal sphincter(LES)pressure and pH(5 cm above LES)between the two groups before and after treatment were compared;the clinical efficacy and adverse drug reactions occurring 3 months after treatment were recorded.Result:Before treatment,there were no significant differences in the symptom scores between the two groups(P>0.05).After treatment,the symptom scores of the two groups showed a downward trend,but the symptom scores of the observation group were significantly lower than the control group(P<0.05).Before treatment,there were no significant differences in serum gastrin level,LES pressure and pH between the two groups(P>0.05).After treatment,the serum gastrin level,LES pressure and pH of the two groups were significantly improved,but the observation group was significantly better than the control group(P<0.05);the total clinical effective rate of the observation group was significantly higher than that of the control group(P<0.05);the incidence of adverse drug reactions in the observation group was significantly lower than that of the control group(P<0.05).Conclusion:The clinical effect of Rabeprazole combined with Mosapride in patients with reflux esophagitis is obvious.It can not only prevent excessive gastric acid from damaging the esophagus,promote stomach and esophagus emptying,prevent reflux,and improve various symptoms.It can also reduce the incidence of adverse drug reactions,has high safety and effectiveness,and is worthy of clinical promotion and application.